Alpine Immune Sciences Inc banner
A

Alpine Immune Sciences Inc
F:34LA

Watchlist Manager
Alpine Immune Sciences Inc
F:34LA
Watchlist
Price: 59 EUR
Market Cap: €4B

Alpine Immune Sciences Inc
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Alpine Immune Sciences Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
A
Alpine Immune Sciences Inc
F:34LA
Change in Working Capital
-$47.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$2.4B
CAGR 3-Years
-109%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
-$3.9B
CAGR 3-Years
-31%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
$10B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
24%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$1.2B
CAGR 3-Years
N/A
CAGR 5-Years
-86%
CAGR 10-Years
-30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
$532.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
9%
No Stocks Found

Alpine Immune Sciences Inc
Glance View

Market Cap
4B EUR
Industry
Biotechnology

Alpine Immune Sciences Inc., a biotechnology company, stands poised at the intersection of innovation and necessity, carving its niche in the fast-paced world of immune system modulation. Founded to address the complex challenges of autoimmune inflammation and cancer, Alpine harnesses the intricate mechanisms of the immune system to develop novel therapies. The company's unique approach centers around their proprietary platform, the "Directed Evolution" technique, which enhances the body's natural defenses by evolving proteins to selectively target cells and pathways. This approach aims to balance efficacy with safety—a critical factor in immunotherapy—to not just treat but possibly transform the landscape of autoimmune and cancer treatments. In this innovative pursuit, Alpine generates revenue through a multi-pronged business model, leveraging both partnerships and proprietary product development. The company actively collaborates with big-name players in the pharmaceutical industry, securing milestone payments, and royalties that provide financial footing. Their pipeline, rich with potential candidates, further positions Alpine for future commercial success, especially as its therapies advance into later stages of clinical trials. By focusing on high-need areas and utilizing strategic collaborations, Alpine Immune Sciences is steadily building a sustainable business model while offering a beacon of hope for patients looking for more effective treatment options.

34LA Intrinsic Value
Not Available
A

See Also

What is Alpine Immune Sciences Inc's Change in Working Capital?
Change in Working Capital
-47.4m USD

Based on the financial report for Mar 31, 2024, Alpine Immune Sciences Inc's Change in Working Capital amounts to -47.4m USD.

What is Alpine Immune Sciences Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
-139%

Over the last year, the Change in Working Capital growth was -139%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett